Category: biotech

.With a strong track record for identifying diamonds in the rough, Bain Financing Lifespan Sciences (BCLS) has become a strong force in biotech trading, attracting

.Invite to recently’s Chutes &amp Ladders, our roundup of substantial management hirings, shootings and retirings across the business. Feel free to send out the good

.Bristol Myers Squibb is actually axing an additional huge wager coming from the Caforio time, canceling a deal for Agenus’ TIGIT bispecific antibody 3 years

.Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell treatments. Perfect, which can receive a whopping $3.5

.Bristol Myers Squibb has possessed a whiplash change of heart on its own BCMA bispecific T-cell engager, stopping (PDF) additional progression months after filing to

.AvenCell Therapies has actually secured $112 thousand in set B funds as the Novo Holdings-backed biotech finds professional evidence that it can easily create CAR-T

.Atea Pharmaceuticals’ antiviral has actually stopped working another COVID-19 trial, however the biotech still holds out wish the prospect has a future in liver disease

.AstraZeneca has settled CSPC Drug Team $100 million for a preclinical cardiovascular disease drug. The package, which deals with a potential competitor to an Eli

.Pinetree Rehabs are going to help AstraZeneca vegetation some trees in its own pipe with a brand new pact to build a preclinical EGFR degrader

.AstraZeneca has actually shared a very early look at the performance of its own in-house antibody-drug conjugate (ADC) technology, publishing period 1 information on applicants